You are here
Pfizer Oncology Press Kit
PLEASE NOTE: All assets on this page are intended for use by media professionals.
At Pfizer Oncology, we are committed to advancing medicines wherever we believe we can make a meaningful difference on the lives of patients. Today, Pfizer Oncology has an industry-leading portfolio of 18 approved innovative cancer medicines and biosimilars across more than 20 indications, including breast, prostate, kidney, lung and hematology. Pfizer Oncology is striving to change the trajectory of cancer.
For the latest information on our growing pipeline, product portfolio and collaborations with the broader cancer community, visit this page periodically for leadership perspective, fact sheets, videos and other media resources. We also encourage you to visit our other online resources for additional information on Pfizer Oncology.
PFIZER AT ASCO
Pfizer will present data across its industry-leading oncology portfolio, covering multiple tumor types and mechanisms of action. This year, our presentations will highlight our cutting-edge approach, expertise in precision medicine and work in immunotherapy combinations, including company-sponsored and collaborative research studies spanning 10 therapies across 10 types of cancer.
Please visit the links below for information on Pfizer Oncology being showcased at ASCO.
PFIZER ABSTRACT PLAIN LANGUAGE SUMMARIES (APLS) AT ASCO
To help interested non-scientists better understand the latest research, we are developing summaries in plain language for Pfizer research results presented at medical conferences. We call these “abstract plain language summaries” (APLS).